On Friday 27 February 2026 at 13:00, Jamal Bousamaki defends his PhD dissertation entitled "Sustaining fibrotic injury in animal models of idiopathic pulmonary fibrosis”.

Idiopathic pulmonary fibrosis (IPF) is a disease in which scar tissue in the lungs reduces the ability to absorb oxygen. The disease is characterized by shortness of breath, a dry cough, reduced physical endurance, and early death. Despite its significant clinical burden, existing therapies available to patients are all non-curative and only slow disease progression. Therefore, it is important to develop new medicines to treat the disease.

In his PhD project, Jamal Bousamaki systematically characterized and validated widely used mouse models of IPF. His research demonstrates that these models differ markedly in how closely they mirror the human disease and in their response to standard-of-care and anti-fibrotic therapies. Importantly, by establishing a model with more sustained lung pathology, his work enables more robust and translational evaluation of novel drug candidates for lung fibrosis.

The project was carried out as a collaboration between Department of Biomedicine, Aarhus University, Aarhus University Hospital, and Gubra A/S, and supported with a PhD grant from Innovation Fund Denmark.

The summary is written by the PhD student.

The defence is public and takes place in Skov Auditorium, Gubra (Hørsholm), or online. Please see the press release for more information. 

Contact

PhD student Jamal Bousamaki
Mail: bousamaki1405@gmail.com 
Phone: +45 91193123

Read full press release